JSH‐23 targets nuclear factor‐kappa B and reverses various deficits in experimental diabetic neuropathy: effect on neuroinflammation and antioxidant defence

Abstract

We observed that NF-κB inhibition partially reversed functional, behavioural and biochemical deficits with JSH-23 treatment. This study substantiates the role of NF-κB activation in the aetiology of diabetic neuropathy and protection afforded by inhibition of NF-κB by JSH-23, which can be attributed to its effect on neuroinflammation and oxidative stress.